Trial Profile
An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation positive previously treated advanced ovarian cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2014
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 02 Jul 2014 New trial record